24 results
20-F/A
2023 FY
BLRX
Bioline Rx Ltd
26 Mar 24
Annual report (foreign) (amended)
4:57pm
commercialize APHEXDA include our ability to access key health care decision makers, price APHEXDA at a sufficient price point to ensure an adequate … health care programs and private health insurers. There is significant uncertainty related to third-party payor coverage and reimbursement of newly
6-K
EX-99
BLRX
Bioline Rx Ltd
30 Aug 23
Current report (foreign)
6:45am
, chargeback payments and rebates granted to managed health care organizations or to national, state and local governments, their agencies, and purchasers
6-K
EX-99
BLRX
Bioline Rx Ltd
21 Jan 21
Amended and Restated Underwriting Agreement
4:32pm
household (regardless of whether such spouse or family member may at the time be living elsewhere due to educational activities, health care treatment
D
BLRX
Bioline Rx Ltd
10 Jun 20
$9M in options / securities to be acquired, sold $9M, 6 investors
8:02am
Services
Oil & Gas
Other Energy
Health Care
Biotechnology
Health Insurance
Hospitals & Physicians
Pharmaceuticals
Other Health Care
Manufacturing
D
sgpss qeo
10 Jun 20
$4.39M in options / securities to be acquired, sold $4.39M, 5 investors
8:00am
6-K
EX-99
7oyak
7 Feb 19
As Representative of the several Underwriters
12:00pm
20-F/A
3pjg2bmt
23 Mar 15
Annual report (foreign) (amended)
12:00am
424B5
jlug3aj1bnudx0 8p
6 Mar 15
Prospectus supplement for primary offering
12:00am
6-K
EX-99.3
uvzdx858z33iowpxw
5 Mar 15
Current report (foreign)
12:00am
424B5
nrl5tw2 q2cm4yy1xf
5 Mar 15
Prospectus supplement for primary offering
12:00am
424B2
tso5lde0amsuj 2vpxg2
13 Jun 14
Prospectus for primary offering
12:00am
F-3
21mk2ey0vdxa
30 May 14
Shelf registration (foreign)
12:00am
424B5
hmh wre4b9d4e2381mq
4 Mar 14
Prospectus supplement for primary offering
12:00am
6-K
EX-99.3
j84erlug3jf2c
3 Mar 14
Current report (foreign)
12:00am
424B5
6q2io
3 Mar 14
Prospectus supplement for primary offering
12:00am
424B3
sozktrn3
8 Aug 13
Prospectus supplement
12:00am